PressOctober 20, 2021 Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups
PressOctober 19, 2021 Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System
PressOctober 18, 2021 Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
PressOctober 15, 2021 Levitee Labs Signs Letter of Intent to Acquire Calgary Addiction and Compounding Pharmacy
PressOctober 12, 2021 Cybin Files an International Patent Application Covering Psychedelic Delivery Methods
PressOctober 11, 2021 Atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression
PressOctober 8, 2021 Tryp Therapeutics To Collaborate With Researchers at The University of Wisconsin-Madison
PressOctober 7, 2021 Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial
PressOctober 6, 2021 PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
PressOctober 5, 2021 Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD
PressOctober 4, 2021 Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
PressSeptember 29, 2021 HAVN Life Acquires Bennett’s Choice Patented Brain Health and Recovery Formulations
PressSeptember 28, 2021 BetterLife Pharma Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
PressSeptember 27, 2021 MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
